

Total annual sales for SBIR/STTR-Supported drugs: over \$36.39 billion*

Drug ¹	Annual Revenue ²	Disease / Condition Treated
Biktarvy	\$11,800,000,000	HIV-1 infection
Imbruvica	\$5,400,000,000	B-cell cancers (CLL, MCL, Waldenström's, MZL)
Soliris	\$3,946,000,000	PNH, aHUS, gMG, NMOSD
Veklury (Remdesivir)	\$2,800,000,000	COVID-19
Ingrezza	\$2,300,000,000	Tardive dyskinesia
Xyrem	\$1,740,000,000	Narcolepsy with cataplexy or EDS
Adcetris	\$1,470,000,000	Hodgkin lymphoma; systemic ALCL
Velcade	\$1,400,000,000	Multiple myeloma; mantle cell lymphoma
Trodelvy	\$1,315,000,000	TNBC; HR+/HER2- metastatic breast cancer
Gattex	\$975,000,000	Short bowel syndrome
Vimizim	\$701,000,000	Morquio A syndrome (MPS IVA)
Nuplazid	\$609,400,000	Parkinson's disease psychosis
Synagis	\$578,000,000	RSV prevention in high-risk infants
Tarceva	\$457,000,000	EGFR-positive NSCLC; pancreatic cancer
Natpara	\$230,000,000	Hypoparathyroidism
Givlaari	\$256,000,000	Acute hepatic porphyria
Oxlumo	\$167,000,000	Primary hyperoxaluria type 1
Tpoxx	\$133,000,000	Smallpox
Ampyra	\$84,600,000	MS-related walking impairment
Margenza	\$17,900,000	HER2-positive metastatic breast cancer
Ongentys	\$13,000,000	Parkinson's disease (OFF episodes)

- Drugs need funding from a variety of sources including public, philanthropic, as well as venture and private capital. SBIR/STTR funding is important funding to de-risk development and act as creditable enhancer and validation. SBIR/STTR is especially valuable for small firms.
- The drugs listed were developed from firms that have received SBIR/STTR funding, according to research performed by the National Academies of Science. This study found that SBIR/STTR awardees generated 12% of all new drugs approved, and 16% of “priority review” drugs.
- Three of the SBIR/STTR-supported Drugs are in the top 25 best selling drugs in the world.
- A majority of the drugs listed are orphan and/or priority drugs

*only include 19 of 103 SBIR/STTR supported drugs which had public revenue. For the other 80% of SBIR/STTR drugs public data was not available.

¹ List of drugs drawn from National Academies of Science report: *Assessment of the SBIR and STTR Programs at the National Institutes of Health (2022)*, **TABLE 5-2.1 NIH SBIR/STTR-funded Firms: Firm-linked NMEs and BLAs, for drugs receiving FDA approval from 1996 to 2020, and a list of previously unpublished list supplied by NAS.**

² Annual revenue sourced from <https://www.evaluate.com/> and <https://www.fiercepharma.com/>

Total annual sales of SBIR/STTR-involved Medical Devices: \$24.6 billion

Company ³	Annual Revenue ⁴	Device / Technology	Disease / Condition Treated
W. L. Gore & Associates	\$4,800,000,000	Vascular grafts, stent-grafts	Aortic aneurysms, peripheral artery disease
Illumina, Inc.	\$4,370,000,000	DNA sequencing platforms	Genetic disease diagnostics; oncology genomics
Genzyme Corporation	\$4,050,000,000	Enzyme replacement therapies	Rare metabolic diseases (Gaucher, Fabry, Pompe, MPS)
DexCom, Inc.	\$4,030,000,000	Continuous glucose monitoring (CGM)	Diabetes (Type 1 & Type 2)
Carl Zeiss Meditec	\$2,066,000,000	Ophthalmic surgical systems & OCT imaging	Cataracts, glaucoma, retinal disease
Integra LifeSciences	\$1,610,000,000	Neurosurgical tools, wound matrices	Brain tumors, trauma, reconstructive surgery
Abiomed, Inc.	\$1,030,000,000	Impella® heart pump	Cardiogenic shock, advanced heart failure
Invitrogen	\$770,000,000	Research reagents	Research use; not tied to a clinical treatment
Thoratec Corporation	\$477,600,000	HeartMate® LVAD	End-stage heart failure
Natus Medical	\$473,400,000	Hearing screening; EEG/neurology tools	Infant hearing loss, epilepsy
CryoLife / Artivion	\$388,500,000	Biologic heart valves; aortic repair devices	Heart valve disease; aortic disease
Glaukos Corporation	\$383,500,000	iStent® MIGS device	Glaucoma
OraSure Technologies	\$185,800,000	OraQuick® rapid tests	HIV, hepatitis C, infectious disease testing
Angel Medical Systems	\$7,100,000	AngelMed Guardian® ischemia detector	Cardiac ischemia detection
HyperBranch Medical Technology	\$1,300,000	Adherus® dural sealant	Neurosurgery; CSF leak prevention
Advanced Breath Diagnostics	\$990,000	Urea breath test	<i>H. pylori</i> infection

- Medical devices need funding from a variety of sources including public, philanthropic, as well as venture and private capital. SBIR/STTR funding is important funding to de-risk development and act as creditable enhancer and validation. SBIR/STTR is especially valuable for small firms.
- The medical devices listed were developed from firms that have received SBIR/STTR funding, according to the 2022 study on the NIH SBIR/STTR program performed by the National Academies of Science. This study found 34 Premarket Approval Applications (PMAs) and 2,475 510K premarket submissions linked to SBIR/STTR.

³ List of companies & Medical devices drawn from National Academies of Science report: Assessment of the SBIR and STTR Programs at the National Institutes of Health (2022), **TABLE 5-2.2** Premarket Approval Applications (PMAs) Linked to NIH SBIR/STTR-Funded Firms from 1996 to 2020

⁴ Annual revenue sourced from publicly available data

STTR-Supported Drugs Highest Annual Sales

\$5.7Billion

Drug ⁵	Annual Revenue ⁶	Company (Originator / Key Developer)	STTR Award?
Ingrezza	\$2,300,000,000	Neurocrine Biosciences	Yes
Trodelvy	\$1,315,000,000	Immunomedics	Yes
Gattex	\$975,000,000	NPS Pharmaceuticals	Yes
Vimizim	\$701,000,000	BioMarin	Yes
Natpara	\$230,000,000	NPS Pharmaceuticals	Yes
Tpoxx	\$133,000,000	SIGA Technologies	Yes
Ampyra	\$84,600,000	Acorda Therapeutics	Yes
Ongentys	\$13,000,000	Neurocrine Biosciences (U.S.)	Yes

Medical devices need funding from a variety of sources including public, philanthropic, as well as venture and private capital. SBIR/STTR funding is important funding to de-risk development and act as creditable enhancer and validation. SBIR/STTR is especially valuable for small firms.

The medical devices listed were developed from firms that have received SBIR/STTR funding, according to research performed by the National Academies of Science.

⁵ List of drugs drawn from National Academies of Science report: *Assessment of the SBIR and STTR Programs at the National Institutes of Health (2022)*, **TABLE 5-2.1 NIH SBIR/STTR-funded Firms: Firm-linked NMEs and BLAs, for drugs receiving FDA approval from 1996 to 2020**, and a list of previously unpublished list supplied by NAS.

⁶ Annual revenue sourced from <https://www.evaluate.com/> and <https://www.fiercepharma.com/>